456 related articles for article (PubMed ID: 19616107)
1. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
4. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
Pugsley MK; Hancox JC; Curtis MJ
Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
[TBL] [Abstract][Full Text] [Related]
5. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
Tabo M; Kimura K; Ito S
J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
[TBL] [Abstract][Full Text] [Related]
6. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
7. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
8. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
9. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
10. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
Holbrook M; Malik M; Shah RR; Valentin JP
J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
[TBL] [Abstract][Full Text] [Related]
11. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
13. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
14. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
15. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
16. QT interval and drug therapy.
Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
[TBL] [Abstract][Full Text] [Related]
17. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
18. Early clinical development: evaluation of drug-induced torsades de pointes risk.
Vik T; Pollard C; Sager P
Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
[TBL] [Abstract][Full Text] [Related]
19. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
20. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]